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Impact of the G84E variant
on HOXB13 gene and protein
expression in formalin-fixed,
paraffin-embedded prostate
tumours
Liesel M. FitzGerald1, Kelsie Raspin 1, James R. Marthick1, Matt A. Field 2,3, Roslyn
C. Malley4,5, Russell J. Thomson6, Nicholas B. Blackburn 1,7, Annette Banks1,
Jac C. Charlesworth1, Shaun Donovan8 & Joanne L. Dickinson 1
The HOXB13 G84E variant is associated with risk of prostate cancer (PCa), however the role this variant
plays in PCa development is unknown. This study examined 751 cases, 450 relatives and 355 controls
to determine the contribution of this variant to PCa risk in Tasmania and investigated HOXB13 gene
and protein expression in tumours from nine G84E heterozygote variant and 13 wild-type carriers.
Quantitative PCR and immunohistochemistry showed that HOXB13 gene and protein expression did
not differ between tumour samples from variant and wild-type carriers. Allele-specific transcription
revealed that two of seven G84E carriers transcribed both the variant and wild-type allele, while five
carriers transcribed the wild-type allele. Methylation of surrounding CpG sites was lower in the variant
compared to the wild-type allele, however overall methylation across the region was very low. Notably,
tumour characteristics were less aggressive in the two variant carriers that transcribed the variant
allele compared to the five that did not. This study has shown that HOXB13 expression does not differ
between tumour tissue of G84E variant carriers and non-carriers. Intriguingly, the G84E variant allele
was rarely transcribed in carriers, suggesting that HOXB13 expression may be driven by the wild-type
allele in the majority of carriers.
Family history is a widely recognised risk factor for prostate cancer (PCa) with an estimated heritability of 58%,
the highest of any cancer1,2. While approximately 33% of familial risk is explained by common, low penetrance
variants, a study by Mancuso and colleagues estimates that as much as 42% of ‘missing’ heritability is likely to be
explained by rare variants3,4. Several recent studies have applied next-generation sequencing (NGS) technologies
to familial PCa datasets with the aim of identifying rare disease-causing variants5–7. In particular, a targeted NGS
study of 94 familial PCa probands, with evidence of linkage to chr17q21, identified a rare non-synonymous mutation in HOXB13 (G84E; rs138213197)5. Ewing and colleagues observed that the case carrier frequency was higher
in a familial cohort, 4.7% (OR 68.1, p = 0.001), compared to a population cohort, 1.4% (OR 20.1, p < 0.001)5.
Several studies have since replicated this finding in Caucasian familial and case-control populations and estimate
the variant to be associated with a 4- to 8-fold increase in PCa risk, as well as with early-onset disease8–14.
In the normal prostate, the highly expressed HOXB13 transcription factor plays a key role in prostate development15. Notably, HOXB13 has been shown to interact with the androgen receptor (AR), a protein essential for
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Figure 1. Segregation of the G84E variant in the familial prostate cancer pedigree, PcTas72. The G84E variant
(+) was originally identified in individuals PcTas72–2 and PcTas72–97 using existing WGS data, with an
additional five carriers identified in subsequent genotyping. Squares indicate males and circles females, with
a slash indicating the subject is deceased. Individual identification numbers and age at diagnosis of cases are
shown under each symbol. An arrow indicates a tumour specimen was obtained.

prostate development and required for all stages of PCa growth16. Norris and colleagues (2009) demonstrated that
HOXB13 acts as both a repressor and coactivator of AR target genes; in target genes with an androgen-response
element (ARE) the HOXB13:AR complex inhibits transcription, but in genes with a HOX element, the complex
enhances transcription16. HOXB13 has been reported to function as a growth promoter and growth suppressor in
prostate cancer models, depending on factors such as tumour androgen sensitivity status and cellular localisation
of the protein (reviewed in17). Therefore, the role of HOXB13 in prostate tumour development remains unclear
and the mechanism by which the HOXB13 gene and, specifically, the G84E variant promotes prostate carcinogenesis, is largely unknown. Further analyses are required to determine whether the G84E variant causes a gain
or loss of gene function, or increases PCa risk through other mechanisms.
The objective of this study was to investigate the functionality of the HOXB13 G84E variant by examining
transcription, translation, and possible epigenetic modification of the gene, in archival prostate tumour specimens obtained from several variant carrier and non-carrier cases identified in a Tasmanian familial PCa cohort.

Results

Identification of the HOXB13 G84E variant in a Tasmanian PCa cohort.

The G84E HOXB13 variant was identified in existing whole-genome sequencing data obtained from a case and his daughter from a
Tasmanian PCa family (Fig. 1; PcTas72–2, and PcTas72–97). Subsequent genotyping of all available PcTas72 family members (n = 61) confirmed the two carriers and identified a further five heterozygous carriers of the G84E
variant, including three cases and two female relatives. Figure 1 shows segregation of the variant in cases from two
branches of PcTas72 but not the third, underscoring the heterogeneity of this cancer, even within a single family.

Association between PCa risk and the HOXB13 G84E variant in the Tasmanian population. To
assess the contribution of the G84E variant to PCa in the Tasmanian population, all individuals from the familial
(n = 699) and case-control (n = 850) PCa cohorts were genotyped. A further 12 variant carriers were identified;
six in five additional PcTas families (Supplementary Table 1), and four in the case-control cohort (three sporadic
cases and one control). We also examined tumour tissue derived from pathology specimens for seven cases from
the six variant carrier families, where germline DNA from blood or saliva was not available, and identified a
further five carriers from two families (Supplementary Table 1). MQLS analysis18 of the combined familial and
case-control genotyping data demonstrated a significant association between PCa risk and the G84E variant in
the Tasmanian population (OR = 6.59; p = 4.2 × 10−5) (Table 1). For the familial cases, the age at diagnosis and
tumour grade of carriers in the six PcTas families were similar to non-carriers in these same families.
The effect of the G84E variant on HOXB13 gene expression. FFPE pathology blocks were obtained
for 22 PcTas cases, 11 of which had G84E carrier status determined from a germline DNA sample (Table 2).
Genotyping of prostate tissue DNA from the 22 blocks confirmed four and identified five additional heterozygous
G84E carriers, including a case whose germline DNA was genotyped as wildtype (PcTas22–203; Table 2). Repeat
genotyping of PcTas22–203 germline and re-extracted tumour DNA samples confirmed the discordant result.
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Familial Cohort - % G84E Carriers Sporadic Cohort - % G84E Carriers ExAC MAF (European/non-Finnish) Odds Ratio
Cases – 3.23% Relatives – 1.34%

Cases – 0.62% Controls – 0.28%

6.59
(p = 4.2 × 10−5)

0.28%

Table 1. MQLS association analysis of G84E and prostate cancer risk in the combined familial and case-control
Tasmanian datasets.

PcTas ID

Age at
Diagnosis

Tissue
Source

Germline
Genotype

Tumour
Genotype

Tumour
Grade1

Contemporary
Gleason Score2

PcTas4–3

80

TURP

CC

CC

M/PD

7 (4 + 3)

PcTas11–11

85

TURP

N/A

CC

—

7 (3 + 4)

PcTas11–12

58

TURP

N/A

CC

—

9 (4 + 5)

PcTas11–13

72

TURP

N/A

CC

—

No tumour

PcTas11–16

78

TURP

N/A

CC

—

5 (2 + 3)

PcTas12–1

63

RP

CC

CC

MD

6 (3 + 3)

PcTas12–6

80

TURP

N/A

CC

PD

7 (3 + 4)

PcTas12–9

68

TURP

N/A

CC

—

6 (3 + 3)

PcTas22–6

63

TURP

CC

CC

WD

No tumour

PcTas47–2

68

TURP

CC

CC

WD

No tumour

PcTas60–1

58

TURP

CC

CC

WD

6 (3 + 3)

PcTas63–24

67

TRUS

N/A

CC

MD

6 (3 + 3)

PcTas72–4

70

TURP

CC

CC

PD

9 (4 + 5)

PcTas12–3

62

TURP

N/A

CT

WD

4 (2 + 2)

PcTas12–7

59

TURP

N/A

CT

PD

9 (4 + 5)

PcTas12–8

73

TURP

N/A

CT

—

6 (3 + 3)

PcTas22–203

79

TRUS

CC

CT

PD

8 (4 + 4)

PcTas22–576

69

RP

N/A

CT

M/PD

7 (3 + 4)

PcTas22–637

70

TRUS

CT

CT

PD

8 (4 + 4)

PcTas72–6

62

TURP

CT

CT

W/MD

5 (3 + 2)

PcTas72–154

63

TRUS

CT

CT

WD

4 (2 + 2)

PcTas3250–1

51

RP

CT

CT

PD

9 (4 + 5)

Table 2. Clinicopathological characteristics of FFPE prostate tissue samples obtained for HOXB13 G84E
carriers and non-carriers. 1Tumour grade obtained from pathology report. 2Contemporary Gleason Score from
FFPE tissue block chosen for macrodissection of nucleic acids and IHC. N/A: germline sample not available.
WD: well differentiated. MD: moderately differentiated; PD. poorly differentiated. -: Information not present in
original pathology report.

First-degree relatives of this individual were genotyped as G84E wildtype. No additional samples were available
for this individual (deceased), therefore this anomaly could not be resolved to determine whether a pathology
sample mix-up had occurred, mosaicism was present in the individual or the variant arose somatically. To investigate HOXB13 gene expression, RNA was extracted from both adjacent benign and malignant cells for 10 cases.
Due to the restricted availability of tissue, RNA was extracted from only benign cells for four cases, only malignant cells for four cases, and a mixed cell population for one case (Supplementary Table 2). HOXB13 expression
was initially investigated in the ten paired malignant-benign samples, where we observed significantly higher
expression in malignant compared to benign cells (1.5-fold increase; p = 0.01; Fig. 2A). However, when HOXB13
expression was compared between the malignant cells of G84E variant carriers (n = 6) and non-carriers (n = 8),
there was no significant difference between the two (p = 0.21; Fig. 2B). There was also no detectable difference in
HOXB13 gene expression between the benign cells of variant carriers (n = 4) and non-carriers (n = 10; p = 0.29).
We next examined whether the variant transcript was detectable in the tumour tissue of seven G84E carriers.
Next-generation sequencing applied to cDNA from freshly cut FFPE sections indicated that only two of seven
variant carriers (28.6%) showed evidence of variant allele transcription (Supplementary Table 2). The variant
transcript was detectable in both malignant and benign cells in one individual and in benign cells only in the
second individual.
To determine whether imbalanced allele transcription was related to HOXB13 G84E carrier status,
allele-specific transcription was determined for another variant in relatively close proximity to the G84E variant.
The HOXB13 variant, rs9900627 (MAF 11.2%), is 262 bp centromeric to G84E in exon 1, and one heterozygous
carrier of this variant was identified in our tissue cohort (PcTas11–11; G84E negative). Unlike carriers of G84E,
the variant and wild-type alleles of rs9900627 were detectable in equal proportions in PcTas11–11.

The effect of the G84E variant on HOXB13 protein expression. Immunohistochemistry was undertaken on all 22 FFPE pathology samples to determine whether protein expression differed between malignant and
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Figure 2. HOXB13 gene expression analysis in FFPE prostate tumours. (A) A 1.5-fold increase in HOXB13
expression was observed in malignant (n = 10) compared to benign cells (n = 10; p = 0.01). (B) No significant
difference in HOXB13 expression was observed between the tumour cells of variant carriers (n = 6) and noncarriers (n = 8; p = 0.21).

Figure 3. HOXB13 protein expression in G84E non-carriers (A and B) and carriers (C and D).
Immunohistochemistry staining intensity of HOXB13 was not consistent with G84E carrier status (A and C)
weak staining; (B and D) strong staining). HOXB13 was predominantly expressed in the nuclei of prostate gland
cells, while cytoplasmic cells were often negative or only weakly positive for the protein. Images were taken on a
Leica 2500 microscope (x200) using the Lieca Application Suite V3.

benign prostate tissue, and between HOXB13 variant and non-variant carriers. HOXB13 staining ranged from
weak to strong across the dataset (Fig. 3; Supplementary Table 2). Analyses of the quasi-continuous nuclear scores
from 16 samples with paired malignant and benign cells did not reveal any significant difference in HOXB13
protein expression between malignant and benign cells (p = 0.45). Analysis of malignant cells from G84E variant carriers (n = 9) versus non-carriers (n = 9) also indicated no significant difference between the two groups
(p = 0.68). A similar result was observed for benign cells (p = 0.84).
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Figure 4. Average methylation (%) across nine CpG sites located within a CpG island surrounding the G84E
variant. Average methylation for both carriers and non-carriers was low across all CpG sites. The variant allele
was less methylated at all sites (solid black line) when compared to the wild-type allele of both variant carriers
(grey solid line) and non-carriers (dotted line). The difference in methylation was statistically significant
between all alleles at CpG site 5, and between the variant allele and the non-carrier wildtype allele at CpG sites 6
and 9 (*p < 0.05, **p < 0.001).

Methylation of HOXB13 CpG islands. We next examined DNA methylation in tumour samples at two
HOXB13 CpG islands, one spanning the promoter region and exon 1 of the gene, and the second located ~4.5 kb
upstream of the HOXB13 transcription start site (Supplementary Figure 1). Allele-specific methylation was
also examined at nine CpG sites within the promoter/exon 1 CpG island and surrounding the G4E variant, to
determine if differential methylation explained the observed unbalanced allele transcription. Very low levels of
DNA methylation were observed across both CpG islands in both variant (n = 3) and non-variant carriers (n = 3;
Supplementary Figure 2). Allele-specific methylation was consistently low across all nine CpG sites within the
promoter/exon 1 CpG island in both variant carriers (n = 7) and non-carriers (n = 7); however, methylation of
the variant allele was lower than that of the wild-type allele in all instances (Fig. 4). Significant differences in
CpG site-specific methylation between the variant allele and wild-type alleles of carriers and/or non-carriers was
observed at three CpG sites (p < 0.05; Fig. 4), while no difference was observed between the wild-type alleles of
carriers and non-carriers. No correlation between methylation and transcription of the variant allele, or absolute
gene expression of HOXB13 was observed (data not shown).

Discussion

The HOXB13 G84E variant is a PCa risk variant reported to be of particular relevance to early onset familial
disease5,19,20. Here, a Tasmanian PCa family was shown to be segregating the HOXB13 variant, which was subsequently demonstrated to be significantly associated with PCa risk in the Tasmanian population (OR = 6.59).
While the HOXB13 gene is known to play a key role in prostate development15 and to interact with the AR to
influence transciption16, little is known about how the HOXB13 G84E variant causes increased PCa risk.
A computational modeling study by Chandrasekaran et al. (2017) has suggested that the G84E variant
increases HOXB13 protein stability21, which may in turn cause increased transcription of downstream target
genes promoting cell proliferation and invasion22. However, in an in vitro cell model study using site directed
mutatgenesis, Cardoso and colleagues (2016) found that the G84E variant had no phenotypic impact, i.e. there
was no change in proliferation or apoptosis compared to the wild-type cell model23. In our study of FFPE prostate
tumour tissue, we found no difference in HOXB13 protein expression between G84E carriers and non-carriers;
a finding supported by a larger IHC study of radical prostatectomy samples from 101 G84E carriers and 99
non-carriers24. Furthermore, we demonstated that gene expression was comparable between carriers and
non-carriers. Although tumour tissue samples from carriers were demonstrated to be heterozygous for the G84E
variant, the variant allele transcript was rarely detectable in G84E carrier prostate tissue (benign or malignant).
In fact, the variant allele was only detectable in two of seven carriers and at lower levels than the wild-type allele.
To further examine HOXB13 allelic expression, transcription of another HOXB13 variant (rs9900627) in close
proximity to G84E was examined. Comparable transcription of both the wild-type and variant rs9900627 alleles
was evident in the tumour tissue of a non-G84E carrier. We therefore hypothesize that the unbalanced allele transcription may be related to the presence of the G84E variant. Unbalanced allele transcription has been reported
previously in a study of breast cancer patients25. Benz et al. (2006) investigated the common ERBB2 variant,
G1170C, in ERBB2-positive and ERBB2-negative breast cancer patients and found that ERBB2-positive germline
heterozygotes had markedly skewed tumour genotype frequencies to homozygosity of either allele and monoallelic transcript amplification25. While this was not unexpected given previous research26,27, when the tumours
of ERBB2-negative germline heterozygotes were examined, Benz et al. found that although tumour genotyping supported the heterozygous state, similar to our study, 70% of tumours showed preferential transcription
of one allele, or unbalanced allele transcription. The authors suggested the unbalanced allele transcription in
ERBB2-negative tumours may be due to epigenetic mechanisms, whereby methylation silences a particular allele.
Two CpG islands are located within or near the HOXB13 gene: the first spans the promoter and exon 1 region
of the gene and the second is ~4.5 kb upstream of the HOXB13 transcription start site28. In a study of colorectal
cancer, Ghoshal and colleagues (2010) found very little methylation in the promoter/exon 1 CpG island in both
ScIenTIfIc ReporTs | (2017) 7:17778 | DOI:10.1038/s41598-017-18217-w

5

www.nature.com/scientificreports/
tumour and normal cell lines, whilst the upstream CpG island was significantly more methylated in tumour
compared to normal cell lines28. Furthermore, they found that hypermethylation of the upstream CpG island
partially supressed HOXB13 expression and speculate that this region may function as an enhancer. In our study,
we observed very low levels of DNA methylation at both CpG islands in all tumour samples tested (G84E carriers and non-carriers). When we looked further at allele-specific methylation of nine CpG sites surrounding the
G84E variant in exon 1, although methylation was lower at three CpG sites on the variant allele, the overall level of
methylation across this region was again so low that the biological impact this would have on gene transcription
is questionable. It therefore seems unlikely that methylation differences explain the unbalanced allele transcription we observe in the G84E carriers. Alternatively, copy number variation at the HOXB13 site or rapid targeted
degradation of the variant mRNA transcript may underpin the observed allelic imbalance and warrants further
investigation.
Interestingly, while the numbers were too small for formal analyses, examination of clinical characteristics
revealed that HOXB13 G84E variant carriers that transcribed the variant allele (PcTas12–3 and PcTas72–6) had
lower tumour grades and Gleason scores (GS) than variant carriers that did not transcribe the variant allele.
The tumours from both PcTas12–3 and PcTas72–6 were well- to moderately-differentiated with GS < 6, whereas
where there was no evidence for variant allele transcription, the tumours were predominantly poorly differentiated with GS ≥ 7, with the exception of one sample (PcTas12–8; GS6). Due to insufficient tumour material,
allele-specific transcription was not able to be determined for two variant carriers, PcTas22–637 and PcTas72–
154, who had a poorly differentiated and well differentiated tumour grade respectively. Several previous studies have investigated possible associations between G84E and clinicopathological factors, and the majority have
found no association between carrier status and GS5,11,29,30. However, two studies have presented contrary results.
A Danish study of 995 patients (25 carriers) found G84E carrier status was significantly associated with GS ≥ 7
versus GS < 731, whilst another study of 1,457 patients (18 carriers) observed that the G84E variant was more
strongly associated with GS ≥ 7(4 + 3) disease but this was not significantly different to the association with
GS ≤ 7(3 + 4) disease13. While it has to again be noted that our observations are based on limited numbers, these
conflicting results may be due to the underlying variability in variant allele transcription that we have observed
and this should be explored in a larger HOXB13 G84E tumour dataset.
This study has provided important insights into the effect the HOXB13 variant has on gene transcription in
prostate tumour tissue but there are some limitations in the interpretation of data. Due to the rarity of the variant
and the limited availability of informative tumour tissue specimens, the number of samples available for G84E
variant carriers was restricted. The quality of DNA and RNA extracted from FFPE tissues is also fairly poor, therefore it is important that our findings are validated in larger FFPE cohorts or, if available, fresh frozen samples. In
our IHC experiment, the antibody used was not specific to the variant form of the HOXB13 protein and it would
be valuable to verify our gene expression results with a variant-specific protein antibody.
In summary, this study has demonstrated that HOXB13 gene and protein expression do not differ in the
tumours of G84E carriers and non-carriers. We have also demonstrated that in our tumour population, only a
minority of variant carriers transcribe the G84E variant allele but the mechanism behind this unbalanced allele
transcription is still unknown. Furthermore, we observed that clinicopathological features tended to be less
aggressive in the tumours of carriers that did transcribe the variant allele. It is important that these findings are
validated in a larger tissue cohort of HOXB13 G84E carriers.

Methods

Study Resource.

Tasmanian Prostate Cancer Familial Cohort. This cohort is comprised of a rare collection of 52 PCa families from the founder population of Tasmania. The number of affected men in these families
range from five to over 140, and include up to five affected brothers and multiple father/son and uncle/nephew
pairs. DNA samples from blood and saliva have been collected for 249 affected men and 450 male and female
relatives. Archived prostate tissue pathology blocks from HOXB13 G84E variant carriers and a random selection of non-carriers were targeted for collection from pathology labs. Sectioned FFPE pathology blocks were
histologically reviewed by RM and SD to provide a contemporary grading of the tumours and to mark regions of
malignant and benign cells.

Tasmanian Case-Control Cohort. The Tasmanian Case-Control Prostate Cancer Study is a population-based
cohort, which includes blood or saliva samples from 495 cases and 355 controls. Cases were identified from the
Tasmanian Cancer Registry (TCR) and considered eligible for this study if they were diagnosed under the age
of 75 between the years 1996 and 2005. Controls were selected at random from the Tasmanian electoral roll and
frequency matched by five year age groups to the cases. Controls are periodically checked against the TCR for
PCa diagnosis.
Ethics approval for both cohort studies was obtained from the Human Research Ethics Committee Tasmania,
Australia (H9999 and H007740) and written informed consent was obtained from all participating individuals.
For deceased familial cases, a waiver of consent was obtained to collect prostate tissue specimens.

Nucleic Acid Extractions. DNA was extracted from blood using the Nucleon BACC3 Kit (GE Healthcare)

and from saliva using the Oragene DNA Kit (DNA Genotek) according to the manufacturers’ directions. FFPE
tissue blocks were sectioned to 8 μm, dewaxed and rehydrated using a standard xylene-ethanol deparaffinisation
protocol. Tumour and benign glands were marked on haematoxylin and eosin stained tissue sections by a pathologist (SD, RM). Marked tumour and benign regions were macro-dissected separately for both DNA and RNA.
DNA was extracted using the QIAamp DNA FFPE Tissue Kit (QIAGEN) according to the manufacturer’s instructions and eluted in 50 μL of ATE Buffer. DNA was quantified using the Nanodrop ND-1000 UV-vis spectrophotometer (Nanodrop Technologies). RNA was extracted using the RecoverAll Total Nucleic Acid Isolation Kit
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(ThermoFisher Scientific) according to the manufacturer’s instructions and eluted in 30 μL of dH2O. RNA quality
and quantity was assessed using the 2100 Bioanalzyer (Agilent). The SuperScriptTM VILOTM cDNA Synthesis Kit
(Invitrogen) was used for cDNA conversion, as per the manufacturer’s instructions.

Next-Generation Sequencing Data. Existing whole-genome and whole-exome sequencing data was
previously generated for several PcTas72 individuals (Fig. 1) at the Illumina Genome Network, USA, on the
HiSeq 2500 s or the Kinghorn Centre for Clinical Genomics, Australia, on the Illumina HiSeq XTM Ten platform
using the TruSeq Nano library preparation. Data had been analysed using the Variant Analysis of Sequenced
Pedigrees (VASP) analytical pipeline, developed specifically to detect disease causing variants in sequenced pedigrees32,33. The presence of the HOXB13 G84E variant was examined in the annotated variant list generated using
the Ensembl Variant Effect Predictor and overlapped with Ensembl canonical transcripts.
Sanger Sequencing. Sanger sequencing was performed to validate the WGS results in the original PcTas72
carriers, as well as determine the HOXB13 variant carrier status of deceased affected men who only had a tumour
specimen available for genotyping. HOXB13 primers were designed using Primer3Plus34,35 (Supplementary
Table 3) and PCR conditions are available on request.
Genotyping.

A TaqMan SNP genotyping assay (Applied Biosystems) was used to genotype the HOXB13
G84E variant in the familial and case-control cohorts on the LightCycler 480 system (Roche). Heterozygous
individuals were confirmed by Sanger sequencing, as described above.

®

Real-Time qPCR Analysis. SYBR green real-time quantitative PCR (qPCR) assays were performed to
determine gene expression of HOXB13 and two housekeeping genes, GAPDH and β-Actin. Amplification was
performed on 50ng FFPE cDNA using published HOXB13, GAPDH and β-Actin primers (Integrated DNA
Technologies; Supplementary Table 3)36,37. Standard curves were generated for HOXB13, GAPDH, and β-Actin to
determine PCR efficiency and normalise absolute HOXB13 gene expression.
MiSeq cDNA Sequencing. Transcription of the wild-type and mutant alleles of HOXB13 were determined
using the MiSeq platform (Illumina). A 157 bp region of HOXB13, covering the G84E mutation, was FFPE cDNA
amplified and barcoded with unique forward and reverse tags (Supplementary Table 3). Barcoded DNA fragments were pooled, purified and libraries were sequenced on the Illumina MiSeq platform using the MiSeq V2
300 Cycle Reagent Kit (Illumina).
FASTQ files were aligned to the hg19 reference genome using Galaxy version 16.04 (usegalaxy.org)38–40. The
raw sequence data (FASTQ files) were converted to Sanger and Illumina 1.8+ format using the FASTQ Groomer
tool, followed by realignment using BWA-MEM. The allele frequency at the variant position was visualised using
IGV 2.3.6841. FastQC of BAM files was used to assess the quality of the raw sequence data.

®

Methylation Analysis. FFPE DNA (~200 ng) was bisulphite converted using the EZ DNA Methylation-GoldTM

Kit (Zymo Research Corp). Two primer sets were designed to amplify fragments covering the HOXB13 promoter/exon
1 CpG island and a CpG island ~4.5 kb upstream of the transcription start site (Supplementary Figure 1; Supplementary
Table 3). Fragments were purified using the QIAquick Gel Extraction Kit (Qiagen), as per the manufacturer’s instructions, and cloned in to the p-GEM -T Easy Vector Kit (Promega Corporation), using a 3:1 ratio of insert to vector.
Top10 competent cells (Invitrogen) were transformed with 2 µL of ligations. Ten white clones per sample were selected
for amplification and DNA extraction, using the QIAprep Spin Miniprep Kit (Qiagen), as per the manufacturer’s
instructions. Clone inserts were sequenced using the reverse Sp6 primer. Each clone CpG site was scored as either 1
(methylated) or 0 (non-methylated), and bubble maps were generated using the CpG Bubble Chart Generator, Version
20061209 Alpha, created by Mark A Miranda.
Allele-specific methylation involved the PCR amplification of a 175 bp region of HOXB13, including the
G84E mutation and nine surrounding CpG sites, using bisulphite-converted FFPE DNA, as described above
(Supplementary Figure 1; Supplementary Table 3). Products were barcoded with unique forward and reverse
tags and sequenced on the Illumina MiSeq platform, as described above. FASTQ files were quality score checked
and separated into reads containing the G84E variant allele or the wild-type allele. A beta value (β), the ratio of
methylated versus non-methylated reads, was determined for all of the nine CpG sites.

®

Immunohistochemistry. Tissue sections (3.5 μm) were pre-treated with Target Retrieval Solution
(Dako), followed by inactivation of endogenous peroxidases using 3% hydrogen peroxidase (Sigma-Aldrich).
Non-specific staining was blocked using Protein Block (Dako). Sections were incubated with primary HOXB13
antibody (sc-28333; Santa Cruz Biotechnology; working dilution 1:50) in a humidified chamber for one hour,
followed by 30 min incubation with an anti-mouse HRP-Labelled Polymer (Dako). HOXB13 protein staining was
visualised with 3–3′ diaminobenzidine (DAB) for 10 min, and the sections were counterstained using Mayer’s
haematoxylin. Normal prostate glands (Abcam), ascertained as HOXB13 wildtype by Sanger sequencing, were
used as positive controls for the immunohistochemical reactions. Negative controls included primary antibody
only, secondary antibody only, and a mouse IgG1 isotype control (Dako).
The immuno-stained sections were scored by a pathology registrar (RM) blinded to the HOXB13 carrier
status. Nuclear staining was scored as none/weak, moderate or strong, depending on the most common staining
intensity in the entire tissue section. Immunostaining was assessed using a quasi-continuous nuclear score, created by multiplying each intensity level (1 for no/weak stain, 2 for moderate stain, and 3 for intense stain) by the
corresponding percentage of positive cells. As benign prostate tissue was also present in some sections, immunostaining was assessed for both tumour and benign cells separately.
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Statistical Analyses. Association analyses. HOXB13 genotype data was analysed using MQLS18, an association analysis that maximises power by performing tests of association in the combined familial and case-control
datasets, while taking into account relatedness of individuals. MQLS uses variance components to examine the
significance of association for related individuals, and when the disease status is known for first-degree relatives of cases, MQLS obtains more power by giving increased weighting to those individuals with closely related
disease-carrying relatives.
Gene expression. The paired Student’s t-test was used to compare absolute HOXB13 gene copy numbers between
tumour and adjacent benign cells. The unpaired Student’s t-test was used to compare absolute HOXB13 gene copy
numbers in the tumour cells of G84E variant carriers versus non-carriers, and in the benign cells of G84E variant
carriers versus non-carriers. P values < 0.05 were considered to be significant. Fold changes were also presented
in box plot format using R version 3.4.0.
Protein expression. The paired Student’s t-test was used to compare HOXB13 protein expression between
tumour and adjacent benign cells. Unpaired Student’s t-tests were used to compare HOXB13 protein expression
in the tumour cells of G84E variant carriers versus non-carriers, and in the benign cells of G84E carriers versus
non-carriers. P values < 0.05 were considered to be significant.
Methylation. Unpaired Student’s t-tests were used to compare methylation (β value) in reads containing the
G84E variant allele versus reads with the wild-type. P values < 0.05 were considered to be significant.

Data Availability.

The data generated during this study are either available in the Supplementary Materials
section or from the corresponding author on reasonable request.
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